It looks like a new trial is about to commence with CAVATAK & KEYTRUDA in advanced NSCLC, to be sponsored by the Olivia Newton-John Cancer Research Institute (with Merck & Viralytics as collaborators).
The trial protocol looks fairly similar to the STORM part B trial (NSCLC component) but it's being conducted in Melbourne, which is great to see.
https://clinicaltrials.gov/ct2/show/NCT02824965?term=NCT02824965&rank=1
.
It looks like a new trial is about to commence with CAVATAK &...
Add to My Watchlist
What is My Watchlist?